Hodgkin's Lymphoma: Current Views on the Problem

Abstract

Lymphogranulomatosis holds a unique position in both oncological and oncohematological studies owing to the extremely polymorphic morphology of tumor tissue, non-specific clinical presentations of the disease, and a high recovery rate ensured by modern treatment protocols. Analysis of the body of literature showed that the development of Hodgkin’s lymphoma is associated with malignant B-cell transformation, which is primarily observed in young people. Histologically, there can be distinguished classical and nodular forms with lymphoid predominance. In the classical form of Hodgkin’s lymphoma, Hodgkin’s and Reed-Sternberg’s cells predominate among tumor cells and are accompanied by reactive inflammation. Modern scientific advances make it possible to perform immunophenotyping of pathological cells and determine the histogenesis of lymphogranulomatosis, however, to the present moment, diagnosing Hodgkin’s lymphoma can pose a significant challenge even for experienced professionals, especially in atypical cases. In most cases, immunohistochemical examination can confirm the diagnosis of classical Hodgkin’s lymphoma. A panel comprising CD3, CD20, CD15, CD30, and PAX5 markers is usually enough for its initial identification. Modern treatment standards of the classical form make it possible to achieve remission in over 80% of cases. However, late complications associated with the impact of specific therapy significantly worsen the outcomes of Hodgkin’s lymphoma treatment. Therefore, choosing the optimal therapy for this category of patients remains controversial. Chemotherapy and radiation regimens need to be improved, as they are often accompanied by side effects and are difficult for patients to tolerate. At present, there is a need for further studies in prevention, diagnosis, and treatment of Hodgkin’s lymphoma.